CLARITIN RAPID DISSOLVE TABLET (ORALLY DISINTEGRATING)

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Beli sekarang

Ciri produk Ciri produk (SPC)
30-04-2020

Bahan aktif:

LORATADINE

Boleh didapati daripada:

BAYER INC

Kod ATC:

R06AX13

INN (Nama Antarabangsa):

LORATADINE

Dos:

10MG

Borang farmaseutikal:

TABLET (ORALLY DISINTEGRATING)

Komposisi:

LORATADINE 10MG

Laluan pentadbiran:

ORAL

Unit dalam pakej:

8/10/30

Jenis preskripsi:

OTC

Kawasan terapeutik:

SECOND GENERATION ANTIHISTAMINES

Ringkasan produk:

Active ingredient group (AIG) number: 0120416001; AHFS:

Status kebenaran:

APPROVED

Tarikh kebenaran:

1998-04-06

Ciri produk

                                _CLARITIN ALLERGY, CLARITIN RAPID DISSOLVE, CLARITIN KIDS RAPID
DISSOLVE & CLARITIN KIDS_
_Page 1 of 40_
PRODUCT MONOGRAPH
CLARITIN
®
ALLERGY
Loratadine Tablets USP 10 mg
CLARITIN
®
RAPID DISSOLVE™
Loratadine Orally Disintegrating Tablets USP 10 mg
Loratadine Orally Disintegrating Tablets USP 5 mg
CLARITIN
®
KIDS RAPID DISSOLVE™
Loratadine Orally Disintegrating Tablets USP 5 mg
CLARITIN KIDS
®
Loratadine Oral Solution USP 1 mg/mL
Histamine H
1
receptor antagonist
Bayer Inc.
2920 Matheson Blvd. E
Mississauga, ON
L4W 5R6
Date of Revision:
April 30
th
, 2020
Submission Control No: 228699
® TM see www.bayer.ca/tm-mc
_CLARITIN ALLERGY, CLARITIN RAPID DISSOLVE, CLARITIN KIDS RAPID
DISSOLVE & CLARITIN KIDS_
_Page 2 of 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.....................................................3
SUMMARY PRODUCT INFORMATION
...............................................................................3
INDICATIONS AND CLINICAL
USE.....................................................................................3
CONTRAINDICATIONS
..........................................................................................................4
WARNINGS AND
PRECAUTIONS.........................................................................................4
ADVERSE
REACTIONS...........................................................................................................5
DRUG INTERACTIONS
...........................................................................................................9
DOSAGE AND
ADMINISTRATION.......................................................................................9
OVERDOSAGE
.......................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
...................................................................11
STORAGE AND
STABILITY.................................................................................................15
SPECIAL HANDL
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Ciri produk Ciri produk Perancis 30-04-2020

Cari amaran yang berkaitan dengan produk ini